Valuation: Precision Therapeutics Inc

Market Cap 140M 123M 116M 106M 198M 13.43B 200M 1.39B 538M 6.86B 526M 515M 22.05B P/E 2026 *
-6.95x
P/E 2027 * -110x
Enterprise Value 140M 123M 116M 106M 198M 13.43B 200M 1.39B 538M 6.86B 526M 515M 22.05B EV / Sales 2026 *
2.32x
EV / Sales 2027 * 0.32x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision Therapeutics Inc

Manager TitleAgeSince
Chief Executive Officer 57 2026-02-08
Director of Finance/CFO - 2026-04-15
President - 2026-03-31
Director TitleAgeSince
Director/Board Member 66 2020-02-18
Chairman 78 2026-02-08
Director/Board Member 60 2020-07-08
Change 5-day change 1-year change 3-year change Capi.($)
-7.56%-8.33% - - 140M
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average -0.68%+2.35%+62.67%+145.08% 30B
Weighted average by Cap. +0.10%+2.86%+79.67%+160.28%

Financials

2026 *2027 *
Net sales 60.4M 53M 50.06M 45.62M 85.39M 5.79B 86M 599M 232M 2.96B 227M 222M 9.51B 431M 378M 357M 326M 610M 41.34B 614M 4.28B 1.66B 21.12B 1.62B 1.58B 67.87B
Net income -41.4M -36.33M -34.31M -31.27M -58.53M -3.97B -58.95M -411M -159M -2.03B -155M -152M -6.52B -4.5M -3.95M -3.73M -3.4M -6.36M -431M -6.41M -44.63M -17.29M -220M -16.9M -16.53M -708M
Net Debt - -
Logo Precision Therapeutics Inc
Axe Compute Inc. is a virtual neocloud AI infrastructure platform. The Company provides customers with access to graphics processing unit (GPU) compute capacity for artificial intelligence (AI) and other high-performance computing workloads through a distributed network model, including infrastructure made available through the Aethir network. It also operates a digital asset treasury focused on the Aethir token (ATH), the native utility token of the Aethir network. Its segments include Compute Services and Treasury Management and Drug Discovery Services. Its Drug Discovery Services segment provides services that include the application of AI using its proprietary biobank of tumor samples, as well as creation of proprietary 3D culture models used in drug development. The Company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two offerings: Axe Compute Access and Axe Compute Build.
Employees
-